Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Candesartan cilexetil
Drug ID BADD_D00347
Description Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00796
KEGG ID D00626
MeSH ID C077793
PubChem ID 2540
TTD Drug ID Not Available
NDC Product Code 62559-641; 70771-1207; 17228-0032; 0378-3224; 46708-341; 62559-642; 63629-2126; 62332-341; 62332-342; 68382-191; 68382-193; 70771-1205; 52562-100; 46708-342; 0378-3232; 70771-1206; 46708-060; 46708-343; 60687-119; 60687-130; 62332-343; 17228-0016; 64220-114; 49884-659; 68382-190; 17228-0017; 65372-1128; 49884-658; 63629-2127; 68382-192; 70518-2719; 70518-2884; 60687-241; 62332-060; 62559-643; 0378-3225; 70771-1204; 17228-0018; 72761-002; 49884-661; 62559-640; 0378-3231; 49884-660
UNII R85M2X0D68
Synonyms candesartan cilexetil | 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate | 1H-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- | Parapres | Kenzen | Amias | Blopress | Atacand | TCV 116 | TCV-116
Chemical Information
Molecular Formula C33H34N6O6
CAS Registry Number 145040-37-5
SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC 6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Osteonecrosis of jaw15.02.04.010; 24.04.05.0050.001262%
Chronic kidney disease20.01.03.0170.001682%
Bone marrow failure01.03.03.005--
Nephritic syndrome20.05.01.0060.001682%-
Adverse reaction08.06.01.0180.001262%-
Low birth weight baby18.04.02.0030.000841%-
Brain injury17.11.01.003; 19.07.03.0070.000841%-
Oropharyngeal pain07.05.05.004; 22.12.03.0160.002103%
Acute kidney injury20.01.03.0160.021867%
Foetal growth restriction18.03.01.0020.001262%
Hepatocellular carcinoma09.04.02.010; 16.07.02.0050.000841%-
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.002523%-
Diffuse alopecia23.02.02.0070.001682%-
Multiple organ dysfunction syndrome08.01.03.0570.000841%
Cornea verticillata06.06.03.0160.002103%-
Bladder transitional cell carcinoma16.08.01.002; 20.03.04.0030.000841%-
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.000841%-
Open angle glaucoma06.03.01.0040.000841%-
Small for dates baby18.04.02.0020.001682%-
Right ventricular dysfunction02.04.02.0330.000841%
Left atrial dilatation02.04.02.0250.001262%-
Facial asymmetry15.10.05.0040.000841%-
Exposed bone in jaw15.02.04.0340.000841%-
Tendon discomfort15.07.01.0120.001262%-
Fine motor skill dysfunction17.01.02.0200.000841%-
Pharyngeal paraesthesia17.02.06.035; 22.04.05.018---
Atypical haemolytic uraemic syndrome01.06.02.003; 07.11.01.032; 17.02.10.027; 20.01.03.0270.000841%-
Bladder transitional cell carcinoma recurrent16.08.01.008; 20.03.04.0120.000841%-
Blood loss anaemia01.03.02.018; 24.07.01.0880.000841%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.001682%-
The 15th Page    First    Pre   15 16    Next   Last    Total 16 Pages